Table 1.
Baseline Characteristics, Mean (±SD) or n(%)
| MrOS cohort (n = 5994) |
Case cohort (n =1000)c |
Nonvertebral fx cases (n=432) |
Hip fx cases (n=81) |
Hip BMD analyses (n=537) |
|
|---|---|---|---|---|---|
| Age (years) | 73.7 (5.9) | 74.6 (±6.2) | 75.5 (±6.4) | 79.8 (±5.9) | 73.4 (±5.8) |
| Race | |||||
| White | 5362 (89.5) | 920 (92.0) | 407 (94.2) | 77 (95.1) | 491 (91.4) |
| African American | 244 (4.1) | 26 (2.6) | 5 (1.2) | 2 (2.5) | 16 (3.0) |
| Asian | 126 (2.1) | 22 (2.2) | 9 (2.1) | 1 (1.2) | 12 (2.2) |
| Hispanic | 191 (3.2) | 23 (2.3) | 10 (2.3) | 1 (1.2) | 11 (2.1) |
| Other | 71 (1.2) | 9 (0.9) | 1 (0.2) | 0 (0.0) | 7 (1.3) |
| Total hip BMD(g/cm2)a | 0.95 (±0.1) | 0.93 (±0.1) | 0.89 (±0.2) | 0.79 (±0.1) | 0.95 (±0.1) |
| Falls in the 1st year of follow-upa | |||||
| 0 falls | 4457 (74.6) | 666 (66.7) | 272 (63.0) | 52 (64.2) | 408 (76.1) |
| 1 fall | 1052 (17.6) | 209 (20.9) | 101 (23.4) | 17 (21.0) | 87 (16.2) |
| ≥2 falls | 467 (7.8) | 124 (12.4) | 59 (13.7) | 12 (14.8) | 41 (7.7) |
| PASE scorea | 146.5 (±68.3) | 145.32 (±68.6) | 142.64 (±72.5) | 121.44 (±65.4) | 150.76 (±65.9) |
| Walk speed (m/s)a | 1.20 (±0.23) | 1.17 (±0.24) | 1.17 (±0.25) | 1.12 (±0.33) | 1.22 (±0.22) |
| Excellent or good health statusa | 5135 (85.7) | 842 (84.3) | 363 (84.0) | 66 (81.5) | 467 (87.1) |
| Chair stand without using armsa | 5865 (98.4) | 970 (97.6) | 413 (96.5) | 74 (93.7) | 529 (98.7) |
| Current smoker | 206 (3.4) | 30 (3.0) | 15 (3.5) | 4 (4.9) | 13 (2.4) |
| Alcohol use (≥7 drinks/wk) | 1549 (25.9) | 243 (24.3) | 98 (22.7) | 15 (18.5) | 137 (25.51) |
| Height (cm)a | 174.1 (±6.8) | 174.1 (±7.1) | 173.6 (±7.2) | 172.5 (±6.2) | 174.7 (±6.8) |
| Weight (kg) | 83.1 (±13.3) | 83.0 (±13.5) | 82.2 (±14.0) | 78.8 (±12.8) | 83.5 (±12.9) |
| BMI (kg/m2) | 27.4 (3.8) | 27.3 (±3.9) | 27.2 (±4.1) | 26.5 (±3.8) | 27.3 (±3.7) |
| Kidney function (eGFRmL/min/1.73m2)a | |||||
| <30 | 28 (0.5) | 5 (0.5) | 1 (0.3) | 0 (0.00) | 5 (0.9) |
| 30–59 | 931 (16.8) | 145 (15.3) | 56 (13.8) | 14 (18.4) | 93 (17.3) |
| ≥60 | 4574 (82.7) | 801 (84.2) | 350 (86.0) | 62 (81.6) | 439 (81.8) |
| Vitamin D supplement usea | 3529 (59.3) | 582 (58.6) | 243 (56.8) | 40 (50.6) | 317 (59.4) |
| Serum vitamin D measuresb | |||||
| Total 25(OH)D(ng/mL) | 24.9 (±7.8) | 24.5 (±7.7) | 20.9 (±7.7) | 25.4 (±7.8) | |
| Total 1,25(OH)2D(pg/mL) | 63.9 (±18.0) | 64.2 (±18.6) | 59.5 (±16.9) | 65.2 (±17.6) | |
a
For the MrOS cohort: 1 missing total hip BMD, 2 missing height, 3 missing PASE, 1 missing health status, 38 missing eGFR, 6missing vitamin D supplement use, 18 missing falls, 34 missing chair stands without using arms.
b
No data for overall MrOS cohort (n = 5994) because vitamin D measures were not obtained from everyone.
c
This cohort includes incident fracture cases (n = 321) and random sample (n = 679).